We need a plan B for no vaccine.
#331
Gets Weekends Off
Joined APC: May 2020
Posts: 484
Developing antibodies are what causes ADE. The second tome you get Covid is worse etc. as to 50 percent immune I have not seen one bit of data on that and you are taking one heck of a leap on the diamond princess. Especially with prison that’s have seen well north of the 70-90 percent infection rates.
#332
It is? Hadn't heard that about COVID-19 (aka SARS-CoV-2). References please. It's a possibility, as are many other biological twists and turns, but I don't think they've concluded that it's anything more than a possibility. No need to panic over hypotheticals.
#333
:-)
Joined APC: Feb 2007
Posts: 7,339
Developing antibodies are what causes ADE. The second tome you get Covid is worse etc. as to 50 percent immune I have not seen one bit of data on that and you are taking one heck of a leap on the diamond princess. Especially with prison that’s have seen well north of the 70-90 percent infection rates.
#334
#336
Different doesn’t mean inferior, pangolin. Just...Well, diverse.
Now about those captive breeding programs...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490220/
Now about those captive breeding programs...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490220/
Last edited by Excargodog; 07-19-2020 at 09:05 AM. Reason: Dating opportunities for Pangolin
#337
Gets Weekends Off
Joined APC: May 2020
Posts: 484
I was replying to Mesabah saying we should let it rip through the country and not use a vaccine due to ADE. If this were true natural infection would be equally as bad. To my knowledge there has not even been a confirmed reinfection just reminding them ADE also occurs naturally I am with you on this one.
#338
#339
Gets Weekends Off
Joined APC: May 2020
Posts: 484
#340
Still no plan B
https://www.nbcnews.com/politics/mee...id-19-n1234742
An excerpt:
An excerpt:
Topher Spiro, vice president of health policy at the left-leaning Center for American Progress, has spent months researching the logistics of inoculating the public against coronavirus once a vaccine is approved.
Potential problems he’s looked at include failing to produce enough glass vials to bureaucratic snafus over who administers the vaccine to simply struggling to convince enough people that it’s safe to get vaccinated. An Associated Press poll this week found 20 percent of respondents said they did not plan to get a vaccine if it became available, with another 31 percent unsure.
“We shouldn't get ahead of ourselves and we should start preparing for the possibility we have a vaccine, but that does not mean we should stop looking for strategies to contain the virus in the meantime,” Spiro said.
Avik Roy, president of the conservative Foundation for Research on Equal Opportunity, co-wrote a coronavirus response framework in April that argued officials should assume for planning purposes that advances in vaccines or treatments don’t materialize.
“I spent a dozen years as an investor in biotech companies,” Roy said. “When you're close to the ground in development of novel treatments, you're acutely aware of how often they fail, how often data that looks promising in the early stages doesn't pan out in the late stages."
Potential problems he’s looked at include failing to produce enough glass vials to bureaucratic snafus over who administers the vaccine to simply struggling to convince enough people that it’s safe to get vaccinated. An Associated Press poll this week found 20 percent of respondents said they did not plan to get a vaccine if it became available, with another 31 percent unsure.
“We shouldn't get ahead of ourselves and we should start preparing for the possibility we have a vaccine, but that does not mean we should stop looking for strategies to contain the virus in the meantime,” Spiro said.
Avik Roy, president of the conservative Foundation for Research on Equal Opportunity, co-wrote a coronavirus response framework in April that argued officials should assume for planning purposes that advances in vaccines or treatments don’t materialize.
“I spent a dozen years as an investor in biotech companies,” Roy said. “When you're close to the ground in development of novel treatments, you're acutely aware of how often they fail, how often data that looks promising in the early stages doesn't pan out in the late stages."
Thread
Thread Starter
Forum
Replies
Last Post
DLax85
Cargo
11
01-18-2017 07:53 PM